Sarepta Therapeutics | SRPT - Selling And Administration Expenses


Sarepta Therapeutics reported $118.61M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Daiichi Sankyo JPY 237.75B 12.21B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 364.27M 12.54M Sep/2026
Insmed USD 253.03M 5.56M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Moderna USD 282M 66M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.31B 325M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026